Arrowhead Pharmaceuticals, Inc. $ARWR Stock Holdings Lessened by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 893,700 shares of the biotechnology company’s stock after selling 63,991 shares during the period. Fisher Asset Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $58,493,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Carolina Wealth Advisors LLC grew its position in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. Optiver Holding B.V. increased its holdings in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc increased its holdings in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 248 shares in the last quarter. QRG Capital Management Inc. raised its position in Arrowhead Pharmaceuticals by 7.1% in the 2nd quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 317 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its position in Arrowhead Pharmaceuticals by 1.8% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 18,814 shares of the biotechnology company’s stock valued at $1,180,000 after purchasing an additional 335 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $47.78 on Monday. The stock’s fifty day moving average price is $63.32 and its two-hundred day moving average price is $71.00. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $37.06 and a 52-week high of $95.49. The company has a debt-to-equity ratio of 16.61, a quick ratio of 4.11 and a current ratio of 4.14. The company has a market cap of $6.73 billion, a price-to-earnings ratio of -9.35 and a beta of 1.34.

Analyst Ratings Changes

A number of research firms have commented on ARWR. Stifel Nicolaus reduced their price objective on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday. The Goldman Sachs Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 24th. They set a “neutral” rating and a $74.00 price target on the stock. UBS Group initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. They set a “buy” rating and a $109.00 price objective on the stock. B. Riley Financial raised their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.93.

Get Our Latest Analysis on Arrowhead Pharmaceuticals

Latest Arrowhead Pharmaceuticals News

These are some of the ARWR news items that stood out recently:

  • Neutral Sentiment: Stifel Nicolaus kept its “buy” rating but lowered its price target to $96 from $104, reflecting a more cautious valuation while retaining a bullish view. Stifel Nicolaus rating
  • Negative Sentiment: For the quarter, Arrowhead reported a $3.00-per-share loss, worse than analysts’ expected $1.52 loss. Revenue of $37.79 million also fell short of the $61.18 million consensus and declined 45.6% year over year, weighing on sentiment around the company’s results. Quarterly earnings report
  • Negative Sentiment: Arrowhead reported a full-year fiscal 2026 loss of $5.11 per share. An earnings analysis also highlights the challenge of making costly R&D pay off as market sentiment toward RNA interference (RNAi) turns more skeptical. Full-year earnings results Earnings analysis

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

(Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Featured Stories

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.